论文部分内容阅读
目的:探讨前列腺按摩液(EPS)中锌离子浓度对Ⅲ型和Ⅳ型前列腺炎诊疗的意义和参考价值。方法:根据NIH前列腺炎分型标准,将入选的173例研究对象分为ⅢA型(n=65)、ⅢB型(n=69)、Ⅳ型(n=39)前列腺炎,并以35例门诊健康体检、无前列腺炎症状者为对照组,检测4组EPS中锌离子浓度,并分析其与慢性前列腺炎症状评分(CPSI),年龄,EPS中白细胞计数、p H值等指标的相关性。结果:ⅢA型及ⅢB型前列腺炎患者EPS中锌离子浓度[(162.2±10.8)、(171.2±12.0)μg/ml]显著低于Ⅳ型及对照组[(234.6±17.9)、(259.5±14.6)μg/ml),P均<0.05]。EPS中锌离子浓度与疼痛评分、生活质量(QOL)评分、症状严重评分以及CPSI总评分均呈显著负相关(r分别为-0.284、-0.232、-0.270、-0.281,P均<0.01),与排尿症状评分无相关。EPS中锌离子浓度与白细胞计数、年龄无明确相关,与p H值呈负相关(r=-0.208,P<0.01)。结论:Ⅲ型和Ⅳ型前列腺炎患者EPS中锌离子浓度低下可能与疼痛等前列腺炎相关症状有关,EPS中锌离子浓度检测对Ⅲ型和Ⅳ型前列腺炎的诊疗具有潜在参考价值。
Objective: To investigate the significance and reference value of zinc ion concentration in prostate massage fluid (EPS) in diagnosis and treatment of type Ⅲ and type Ⅳ prostatitis. Methods: According to NIH classification of prostatitis, 173 cases were divided into three groups: type A (n = 65), type ⅢB (n = 69) and type Ⅳ (n = 39) The health examination and no symptoms of prostatitis were taken as the control group. The concentrations of zinc ion in four groups of EPS were detected and the correlations were analyzed with CPSI, age, white blood cell count and p H value in EPS. Results: The levels of zinc ion in EPS of type ⅢA and ⅢB prostatitis were significantly lower than those of type Ⅳ and control [(162.2 ± 10.8), (171.2 ± 12.0) μg / ml] [(234.6 ± 17.9) and (259.5 ± 14.6 ) μg / ml), all P <0.05]. The levels of zinc in EPS were negatively correlated with pain scores, quality of life (QOL) scores, severe symptom scores and total CPSI scores (r = -0.284, -0.232, -0.270, -0.281, P <0.01, respectively) There was no correlation with voiding symptom score. There was no significant correlation between zinc ion concentration and leukocyte count and age in EPS, but negatively correlated with p H value (r = -0.208, P <0.01). CONCLUSIONS: The low zinc ion concentration in EPS of patients with type III and IV prostatitis may be related to the symptoms associated with prostatitis such as pain. The detection of zinc ion in EPS may be a potential reference for the diagnosis and treatment of type III and IV prostatitis.